Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 3:21 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 97–120 of 1,487 matching trials from the live ClinicalTrials.gov search.

Filters: Evanston, Illinois Clear all

Conditions: Gliosarcoma, MGMT-Unmethylated Glioblastoma
Interventions: Contrast-enhanced Magnetic Resonance Imaging, Ipilimumab, Nivolumab, NovoTTF-100A Device, Quality-of-Life Assessment, Questionnaire Administration, Radiation Therapy, Temozolomide; Procedure · Biological · Device + 3 more
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 159 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2025
U.S. locations: 285
States / cities: Birmingham, Alabama • Little Rock, Arkansas • Anaheim, California + 210 more

Conditions: Acute Myeloid Leukemia
Interventions: Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Decitabine and Cedazuridine, Enasidenib, Venetoclax; Procedure · Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 93 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 136
States / cities: Tucson, Arizona • Little Rock, Arkansas • Berkeley, California + 115 more

Conditions: Carcinoma, Transitional Cell, Urinary Bladder Neoplasms, Neoplasm Metastasis
Interventions: Vepugratinib, Placebo, EV, Pembrolizumab; Drug · Other
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 450 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2033
U.S. locations: 64
States / cities: Tucson, Arizona • Little Rock, Arkansas • Irvine, California + 48 more

Conditions: Hypertension
Interventions: clevidipine, nitroglycerin; Drug
Lead sponsor: The Medicines Company; Industry
Eligibility: 18 Years and older
Enrollment: 629 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2005
U.S. locations: 28
States / cities: Birmingham, Alabama • Montgomery, Alabama • Tucson, Arizona + 19 more

Conditions: Breast Cancer
Interventions: systemic chemotherapy, axillary lymph node dissection, neoadjuvant therapy, sentinel lymph node biopsy, therapeutic conventional surgery, ultrasound imaging; Drug · Procedure
Lead sponsor: Alliance for Clinical Trials in Oncology; Other
Eligibility: 18 Years and older · Female only
Enrollment: 756 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2023
U.S. locations: 324
States / cities: Mobile, Alabama • Anchorage, Alaska • Little Rock, Arkansas + 232 more

Conditions: Pancreatic Cancer
Interventions: Not listed
Lead sponsor: NewLink Genetics Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 15
States / cities: Los Angeles, California • Palo Alto, California • Gainesville, Florida + 12 more

Conditions: Prostate Cancer
Interventions: TAK-700, Bicalutamide; Drug
Lead sponsor: SWOG Cancer Research Network; Network
Eligibility: 18 Years and older · Male only
Enrollment: 1,313 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2025
U.S. locations: 560
States / cities: Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 374 more

Conditions: Colorectal Neoplasms
Interventions: Third Eye Retroscope; Device
Lead sponsor: Avantis Medical Systems; Industry
Eligibility: Not listed
Enrollment: 328 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009
U.S. locations: 9
States / cities: Celebration, Florida • Chicago, Illinois • Evanston, Illinois + 5 more

Conditions: Prostate Cancer
Interventions: Ipilimumab; Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older · Male only
Enrollment: 54 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2027
U.S. locations: 3
States / cities: Evanston, Illinois • New York, New York • Portland, Oregon

Conditions: ST Elevation (STEMI) Myocardial Infarction of Anterior Wall
Interventions: Impella CP® placement prior to reperfusion with Primary PCI; Device
Lead sponsor: Abiomed Inc.; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 527 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2030
U.S. locations: 46
States / cities: Birmingham, Alabama • Scottsdale, Arizona • Tucson, Arizona + 41 more

Conditions: Pelvic Pain
Interventions: Relugolix (40 mg) /estradiol (1 mg)/norethisterone acetate (0.5 mg) oral tablet; Drug
Lead sponsor: Endeavor Health; Other
Eligibility: 18 Years to 35 Years · Female only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Evanston, Illinois

Conditions: Primary IgA Nephropathy
Interventions: Nefecon, Placebo oral capsule; Drug
Lead sponsor: Asahi Kasei Therapeutics, AB; Industry
Eligibility: 18 Years and older
Enrollment: 365 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2023
U.S. locations: 34
States / cities: Birmingham, Alabama • Tucson, Arizona • Palo Alto, California + 28 more

Conditions: Heart Failure With Preserved Ejection Fraction
Interventions: AZD4831, Placebo; Drug · Other
Lead sponsor: AstraZeneca; Industry
Eligibility: 40 Years to 85 Years
Enrollment: 711 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 21
States / cities: Alexander City, Alabama • Little Rock, Arkansas • Sacramento, California + 18 more

Conditions: Renal Insufficiency, Chronic
Interventions: paricalcitol; Drug
Lead sponsor: Abbott; Industry
Eligibility: 18 Years and older
Enrollment: 68 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2002
U.S. locations: 18
States / cities: Tucson, Arizona • Pasadena, California • San Diego, California + 15 more

Conditions: Type 1 Diabetes
Interventions: t:slim X2 insulin pump with Control-IQ technology 1.5; Device
Lead sponsor: Tandem Diabetes Care, Inc.; Industry
Eligibility: 6 Years to 80 Years
Enrollment: 183 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 13
States / cities: Orange, California • Palo Alto, California • Aurora, Colorado + 10 more

Conditions: Glioblastoma Multiforme
Interventions: Bevacizumab and Temozolomide; Drug
Lead sponsor: University of Chicago; Other
Eligibility: 18 Years and older
Enrollment: 62 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2014
U.S. locations: 5
States / cities: Chicago, Illinois • Evanston, Illinois • Ann Arbor, Michigan + 2 more

Conditions: Aortic Valve Stenosis
Interventions: LOTUS Edge Valve System; Device
Lead sponsor: Boston Scientific Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 382 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 49
States / cities: Huntsville, Alabama • Tucson, Arizona • Little Rock, Arkansas + 39 more

Conditions: Nipple Sparing Mastectomy
Interventions: Nipple Sparing Mastectomy; Procedure
Lead sponsor: Intuitive Surgical; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2026
U.S. locations: 5
States / cities: Evanston, Illinois • Rochester, Minnesota • Queens, New York + 2 more

Conditions: Heart Failure
Interventions: Empagliflozin 10 mg Tab, Placebo Oral Tablet; Drug
Lead sponsor: Saint Luke's Health System; Other
Eligibility: 19 Years to 119 Years
Enrollment: 65 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 10
States / cities: Los Angeles, California • Jacksonville, Florida • Evanston, Illinois + 7 more

Conditions: Dyslipidemias, High Cholesterol, Hypercholesterolemia
Interventions: Obicetrapib; Drug
Lead sponsor: NewAmsterdam Pharma; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021
U.S. locations: 19
States / cities: Anniston, Alabama • Huntington Park, California • Los Angeles, California + 15 more

Conditions: Ovarian Cancer, Primary Peritoneal Cavity Cancer
Interventions: enzastaurin hydrochloride; Drug
Lead sponsor: Gynecologic Oncology Group; Network
Eligibility: 18 Years to 120 Years · Female only
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2006
U.S. locations: 16
States / cities: Los Angeles, California • Chicago, Illinois • Decatur, Illinois + 13 more

Conditions: Hypercholesterolemia
Interventions: Alirocumab, Placebo (for alirocumab), Lipid Modifying Therapy (LMT); Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older
Enrollment: 486 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 26
States / cities: Bell Gardens, California • Long Beach, California • Los Angeles, California + 21 more

Conditions: Radial Head Fractures
Interventions: Not listed
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years to 90 Years
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 3
States / cities: Chicago, Illinois • Evanston, Illinois

Conditions: Lung Cancer
Interventions: topotecan hydrochloride; Drug
Lead sponsor: Case Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2001
U.S. locations: 53
States / cities: Birmingham, Alabama • Phoenix, Arizona • Bakersfield, California + 48 more

Search by objective public record fields.

Testing the Use of the Immunotherapy Drugs Ipilimumab and Nivolumab Plus Radiation Therapy Compared to the Usual Treatment (Temozolomide and Radiation Therapy) for Newly Diagnosed MGMT Unmethylated Glioblastoma

Comparing New Treatments for People With Newly Diagnosed Acute Myeloid Leukemia That Has an IDH2 Gene Change (A MyeloMATCH Treatment Trial)

A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract

Clevidipine in the Perioperative Treatment of Hypertension (ECLIPSE-NTG)

Surgery to Remove the Sentinel Lymph Node and Axillary Lymph Nodes After Chemotherapy in Treating Women With Stage II, Stage IIIA, or Stage IIIB Breast Cancer

Long Term Follow-Up Study for Subjects Previously Treated With Algenpantucel-L (HyperAcute-Pancreas) Immunotherapy

S1216, Phase III ADT+TAK-700 vs. ADT+Bicalutamide for Metastatic Prostate Cancer

Impact of Experience on Results With the Third Eye Retroscope

Combining Ipilimumab With Abiraterone Acetate Plus Prednisone in Chemotherapy and Immunotherapy-naïve Patients With Progressive Metastatic Castration-resistant Prostate Cancer

Primary Unloading and Delayed Reperfusion in ST-Elevation Myocardial Infarction: The STEMI-DTU Trial

Phenotyping of Idiopathic Pelvic Pain With Real-time Uterine Imaging and Relugolix-Combination Therapy Treatment

Efficacy and Safety of Nefecon in Patients With Primary IgA (Immunoglobulin A) Nephropathy

Study to Evaluate the Efficacy and Safety of AZD4831 in Participants With Heart Failure With Left Ventricular Ejection Fraction > 40%

Safety and Efficacy of Zemplar Capsule in Reducing Serum iPTH Levels in Chronic Kidney Disease Subjects (Three Times Weekly)

Safety Evaluation of an Advanced Hybrid Closed Loop System Using Lyumjev With the Tandem t:Slim X2 Insulin Pump With Control-IQ Technology in Adults, Adolescents and Children With Type 1 Diabetes

Bevacizumab and Temozolomide Following Radiation and Chemotherapy for Newly Diagnosed Glioblastoma Multiforme

REPRISE IV: LOTUS Edge Valve System in Intermediate Surgical Risk Subjects

Open Nipple Sparing Mastectomy (NSM)

Empagliflozin Impact on Hemodynamics in Patients With Heart Failure

Randomized Study of Obicetrapib as an Adjunct to Statin Therapy

Enzastaurin in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer or Primary Peritoneal Cancer

Efficacy and Safety of Alirocumab (SAR236553/REGN727) Versus Placebo on Top of Lipid-Modifying Therapy in Patients With Heterozygous Familial Hypercholesterolemia Not Adequately Controlled With Their Lipid-Modifying Therapy

Comparison of Two Radial Head Implants

Topotecan in Treating Patients With Relapsed Small Cell Lung Cancer